HomeCompareAAPGV vs NOBL

AAPGV vs NOBL: Dividend Comparison 2026

AAPGV yields 11.51% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AAPGV wins by $19.9K in total portfolio value
10 years
AAPGV
AAPGV
● Live price
11.51%
Share price
$17.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.8K
Annual income
$2,362.57
Full AAPGV calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — AAPGV vs NOBL

📍 AAPGV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAAPGVNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AAPGV + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AAPGV pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AAPGV
Annual income on $10K today (after 15% tax)
$978.14/yr
After 10yr DRIP, annual income (after tax)
$2,008.18/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, AAPGV beats the other by $1,798.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AAPGV + NOBL for your $10,000?

AAPGV: 50%NOBL: 50%
100% NOBL50/50100% AAPGV
Portfolio after 10yr
$32.8K
Annual income
$1,304.38/yr
Blended yield
3.98%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AAPGV buys
0
NOBL buys
0
No recent congressional trades found for AAPGV or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAAPGVNOBL
Forward yield11.51%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$42.8K$22.8K
Annual income after 10y$2,362.57$246.19
Total dividends collected$17.5K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AAPGV vs NOBL ($10,000, DRIP)

YearAAPGV PortfolioAAPGV Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$11,851$1,150.75$10,914$214.34+$937.00AAPGV
2$13,955$1,274.51$11,897$218.63+$2.1KAAPGV
3$16,334$1,402.61$12,952$222.72+$3.4KAAPGV
4$19,012$1,534.36$14,086$226.62+$4.9KAAPGV
5$22,012$1,669.06$15,302$230.33+$6.7KAAPGV
6$25,359$1,806.01$16,607$233.85+$8.8KAAPGV
7$29,078$1,944.49$18,007$237.18+$11.1KAAPGV
8$33,198$2,083.84$19,508$240.35+$13.7KAAPGV
9$37,745$2,223.40$21,116$243.35+$16.6KAAPGV
10$42,750$2,362.57$22,841$246.19+$19.9KAAPGV

AAPGV vs NOBL: Complete Analysis 2026

AAPGVStock

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Full AAPGV Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this AAPGV vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AAPGV vs SCHDAAPGV vs JEPIAAPGV vs OAAPGV vs KOAAPGV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.